A Unifying Pathophysiologic Approach to The Complications of Diabetes in the Context of the Beta-cell Classification of Diabetes: A Framework for Understanding.

Slides:



Advertisements
Similar presentations
1 Diagnosis of Type 1 Diabetes. 2 Classifying Diabetes IAA, autoantibodies to insulin; GADA, glutamic acid decarboxylase; IA-2A, the tyrosine phosphatase.
Advertisements

HISTORY OF MONOGENIC DIABETES Graeme Bell Advances in Monogenic Diabetes Care and Research Chicago, IL Saturday, July 20, 2013.
Autosomal dominant inheritance Risks to children where both parents are affected: the basics a tutorial to show how the genes segregate to give the typical.
Obesity Projects: Lessons Learned and Relearned Daniel E. Hale, M.D Professor of Pediatrics, UTHSCSA.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Reducing the Risk of T2DM: What Works?
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Therapy of Type 2 Diabetes Mellitus: UPDATE
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Diagnosing Diabetes In Adults– Type 1, LADA, or Type 2? Stanley Schwartz MD, FACE, FACP Affiliate Main Line Health Emeritus, Clinical Assoc. Prof. of Medicine.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM (Part 1) Stan Schwartz MD, FACP, FACE.
Diagnosing Diabetes In Adults– Type 1, LADA, or Type 2? Stanley Schwartz MD, FACE, FACP Affiliate Main Line Health Emeritus, Clinical Assoc. Prof. of Medicine.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
How Can We Cure Diabetes? Clayton E. Mathews, Ph. D. Department of Pathology Diabetes Center of Excellence University of Florida College of Medicine.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.
Understanding Genetic Testing
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations.
Current Classification of DM Update on Diabetes Classification Celeste C. Thomas, MD, MSa,*, Louis H. Philipson, MD, PhD,Med Clin N Am 99 (2015) 1–16.
Diagnosing Diabetes In Adults– Type 1, LADA, or Type 2? Stanley Schwartz MD, FACE, FACP Affiliate Main Line Health Emeritus, Clinical Assoc. Prof. of Medicine.
For Now, with Current Terminology, Cost- Driven ‡ BASED ON FAMILY HX (GENES) AGE, ?KETOSIS PRONE BMI, ANTIBODIES If cost ‘less of an Issue’- antibodies.
Pathogenesis and biological interventions in T1DM- LIKE autoimmune diabetes- Insulitis The class I MHC molecules are hyperexpressed on the β-cell surface.
Diagnosing Diabetes Mellitus in Adults: Type 1, LADA, Type 2 Stanley Schwartz MD, FACE, FACP Affiliate, Main Line Health System Emeritus, Clinical Assoc.
TYPE 1 DIABETES UPDATE Colorado Association for School-Based Health Care G. Todd Alonso, MD May 6, 2016.
Efficacy of Immunotherapy in T1DM: Some Can Delay Decline in C-peptide
Avoid Early Insulin Therapy (except in Ketosis-prone) Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Blood glucose rises.
The β-Cell Centric Classification of DM
Visfatin in Type 2 Diabetes Mellitus
Beta-Cell Classification of Diabetes and the Egregious Eleven: Logic for Newer Algorithms/ Processes of Care The Role of Newer Anti-Diabetes Medications.
Pathophysiology of Type 1 Diabetes
A Clinical-Translator’s Point-of-View:
Metformin treatment in a boy with HNF-1A mutation and criteria of T2DM
Unified Theory of Diabetes and All Its Complications
Whole Blood Vs. Plasma Glucose Levels
Targets for Therapies/ New Guidelines
Burden of Type 1 Diabetes
Diabetes Mellitus.
Pushback What about ‘pure’ Insulin Resistance Syndromes?
Young Children with Type 1 Diabetes Mellitus Have Low Rate of Partial Remission Sasigarn A. Bowden, Mary Duck, Robert P Hoffman Division of Endocrinology,
Identifying monogenic diabetes
University of Colorado
Diabetes Mellitus.
Diagnosis of Type 1 Diabetes
Figure 2 Pathophysiology of hyperglycaemia in T2DM
Type 1 Diabetes Mellitus
Macrovascular Complications Microvascular Complications
Nat. Rev. Endocrinol. doi: /nrendo
The β-Cell Centric Classification of DM
Beta-Cell Classification of Diabetes and the Egregious Eleven: Logic for Newer Algorithms/ Processes of Care The Role of Newer Anti-Diabetes Medications.
WHAT ABOUT COMPLICATIONS OF DIABETES?
The Future Use of Technology in Outpatient Care Using the Computerized Patient Record to Implement Principles of Disease Management: Focus on the.
Insulin Therapy & Vascular Function : Logic for New Approaches to Diabetes Care: A Translational and Evidence-Based Practice Interpretation Stan Schwartz.
ANTIBODIES VARIABILITY IN TYPE 1 DIABETES-Clinical implications?
Nat. Rev. Endocrinol. doi: /nrendo
Clinical Genomics in Inflammatory Bowel Disease
Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.
Nat. Rev. Cardiol. doi: /nrcardio
New diabetes stratification
The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.
“Time to Stop Passing the Buck: What Every Cardiologist in 2019 Needs to Know About Cardiometabolic Risk Reduction and the Treatment of Diabetes Mellitus”
Burden of Type 1 Diabetes
Schematic depiction of three stages of the natural history of T2D, noting several opportunities for improvement of management. Schematic depiction of three.
Twice daily regimen N=45 MDI regimen N=28 P Value
Presenter Disclosure Information (SAMPLE DISCLOSURE SLIDE)
Presentation transcript:

A Unifying Pathophysiologic Approach to The Complications of Diabetes in the Context of the Beta-cell Classification of Diabetes: A Framework for Understanding and Managing DM Stanley Schwartz MD, FACE, FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor of Medicine University of Pennsylvania stschwar@gmail.com

I cannot teach anybody anything, I can only make them think Socrates (470-399 B.C.)  

Stanley Schwartz MD Disclosures Research Support: 0 Employee: 0 Board Member/Advisory Panel: Janssen, Merck, AZ-BMS, BI-Lilly, Salix, Novo, Genesis Biotechnology Group Stock/Shareholder: Saturn EMR Decision Support APP., Flairz, ARKAY Consultant: NIH RO1 DK085212, Struan Grant PI Speaker’s Bureaus: Janssen, Merck, Novo, Salix, BI-LILLY, Eisai, AZ-Int’l, Amgen

Value of Appropriate Classification of DM DM diagnostics need to be pragmatic Appropriate classifications permits us to: PREDICT risk of DM PREVENT advancement of DM PLAN treatment strategy PROMOTE informed research directions Current diagnostics do none of the above

Current DM Classification Failing T1DM= Immune destruction of β-cells T2DM= Insulin Resistance This distinction has been used as basis of distinction between T1D, and T2D BUT WE’VE LEARNED SO MUCH MORE The four types of diabetes include: The typical child with type 1 diabetes; Early onset of type 2 diabetes, particularly in non-Caucasian groups; An atypical form of diabetes sometimes with fluctuating insulin dependency, seen in African Americans; and The very rare “maturity onset diabetes of youth” (MODY), which has been found to be related to identifiable genetic mutations, transmitted in an autosomal dominant pattern, and virtually always in Caucasians.

EG: I was asked how to Diagnose Diabetes Mellitus in Adults: Type 1, Type 2, LADA WE SAW That Confusion Abounds, Definitions Imprecise Diagnosis is often imprecise/ or overlapping phenotypes Flatbush DM- present in DKA- ‘turn out to be T2DM’ LADA- Adults who look like ‘typical T1DM’ Antibody positive patients who look like ‘T2DM’ T1DM with Insulin Resistance (like T2DM)

Comparing Definitions for T1D, ‘LADA’, T2D IMMUNITY AGE GENES BMI INSULIN THERAPY child adult low normal high HLA++ HLA+ HLA ? Strong +++ ++ + weak Immediate Variable Infrequent T1D In children In adults LADA T2D Adapted from Leslie et al. Diabetes Metab Res Rev. 2008 Oct;24(7):511-9

Diabetes is a Continuum OF β-cell DYSFUNCTION Issue is not ‘What is LADA,T1DM, T2DM?’ Issue is: WHAT ARE MECHANISMS And RATE OF DESTRUCTION OF β-cells in a given patient Groop et al. 2014 This ‘vantage point’ also informs best treatment course

CLASSIFICATION/ DIAGNOSIS IS IMPORTANT Isn’t it Time for A New Classification Schema for the Diagnosis and Treatment of Diabetes Mellitus (DM)